HalioDX are now part of the Veracyte family
We are very pleased to announce today the acquisition of HalioDx by Veracyte.
Veracyte is a global genomic diagnostics company focused on improving care at every step of the patient journey in cancer and other diseases.
This is a tremendous milestone for both companies and the newly formed team is fully committed to make this acquisition a great success.
For the past 6 years, HalioDx has been committed to its principal mission to become the leader in immuno-oncology diagnostics and research by leveraging our scientific expertise to develop a cutting-edge portfolio of immune-based assays. This acquisition by Veracyte will strengthen this industry leading position and will provide our partners the opportunity to access an even broader portfolio of tests and services.
What does it mean for you?
- Our relationships come first, this transition will not impact your engagements with us. As always, we prioritize our privileged relationship with you, and we will continue to go to any extent to ensure highest level of satisfaction. Your primary contacts with our team will remain the same.
- For the processing and testing of your samples, HalioDx’s operations and laboratories remain in Marseille, France and Richmond, Virginia and there will be no impact on current processes and projects.
- Related to our change to Veracyte, our documentation and branding will be updated, and we will directly provide you with further details on the modifications that will occur in this regard.
For any additional questions that you may have, please feel free to reach out to your primary contact.
We sincerely thank you for your trust and are looking forward to continuing working with you